X
[{"orgOrder":0,"company":"Enterprise Therapeutics","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$96.8 milion","newsHeadline":"Enterprise Therapeutics\u2019 TMEM16A Potentiator Program for Treatment of Cystic Fibrosis and Other Respiratory Diseases Acquired by Roche","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase I","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Enterprise Therapeutics"},{"orgOrder":0,"company":"NeRRe Therapeutics","sponsor":"Columbus Venture Partners","pharmaFlowCategory":"D","amount":"$27.8 million","upfrontCash":"Undisclosed","newsHeadline":"NeRRe Therapeutics Raises \u00a320 Million in a Series B2 Financing Round","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase I","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"NeRRe Therapeutics"}]
Find Clinical Drug Development Pipelines & Deals | PipelineProspector
Filters
Details:
New funds to evaluate orvepitant as a treatment for the disabling chronic cough associated with idiopathic pulmonary fibrosis (IPF). The chronic cough can markedly reduce quality of life, is often refractory to medical therapy and there are no approved treatments for it.
Lead Product(s):
Orvepitant Maleate
Therapeutic Area: Pulmonary/Respiratory Diseases
Product Name: GW823296X
Highest Development Status: Phase I
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Columbus Venture Partners
Deal Size: $27.8 million
Upfront Cash: Undisclosed
Deal Type: Series B Financing
July 07, 2021
Details:
Enterprise Therapeutics' TMEM16A portfolio includes ETD002, first of its compounds to hit clinical stage. In pre-clinical models the compound has been found to enhances the activity of TMEM16A.
Lead Product(s):
ETD002
Therapeutic Area: Pulmonary/Respiratory Diseases
Product Name: ETD002
Highest Development Status: Phase I
Product Type: Small molecule
Partner/Sponsor/Collaborator:
F. Hoffmann-La Roche
Deal Size: Undisclosed
Upfront Cash: $96.8 milion
Deal Type: Acquisition
October 07, 2020